Psychiatric Times · Phase 3 Trial · 2026-04-10
PromisingCOMP360 psilocybin meets primary endpoint in Phase 3 treatment-resistant depression
Why it matters. A Phase 3 primary-endpoint success for psychedelic-assisted therapy in treatment-resistant depression is notable; review the full report for magnitude and durability.
Provenance
- Source
- Psychiatric Times
- Source type
- news
- Content analyzed
- metadata only
Evidence grading reflects the portion of the source actually analyzed. Always confirm against the original before acting.
Your read
Post your interpretation for colleagues. Every post stays anchored to this source, no empty-box updates.
Sign in to post your read of this evidence.